The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data
30 Pages Posted: 13 Aug 2006 Last revised: 2 Jan 2023
Date Written: August 2006
Abstract
We estimate the medical cost per life-year gained from increased utilization of HIV drugs by estimating the impact of increased drug utilization on the life expectancy and drug and hospital expenditure of HIV/AIDS patients, using aggregate (U.S. national-level) data for the period 1982-2001. We use IMS Health data on the aggregate number of and expenditure on HIV drug prescriptions, the CDC's AIDS Public Information Data Set, and data from AHRQ's Nationwide Inpatient Sample.Estimates of mortality models imply that actual life expectancy of HIV/AIDS patients in 2001 was 13.4 years higher than it would have been if the drug utilization rate had not increased from its 1993 level. Estimates of a model of hospital discharges imply that increased utilization of HIV drugs caused hospital utilization to decline by .25 to .29 discharges per person per year during the period 1993-2001. Medical cost per additional life-year is estimated to have been $17,175.Treatments that cost this amount are widely considered to be cost-effective. The consistency of this estimate with those from previous studies suggests that analysis of aggregate data may be a useful alternative or additional approach to evaluating the cost-effectiveness of new treatments.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Accounting for Future Costs in Medical Cost-Effectiveness Analysis
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments
By Mark Duggan and William N. Evans
-
Insurance and Incentives for Medical Innovation
By Alan M. Garber, Charles I. Jones, ...
-
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets
-
By Tomas Philipson and Anupam B. Jena
-
Advances in Cost-Effectiveness Analysis of Health Interventions
-
The Welfare Effects of Public Drug Insurance
By Darius N. Lakdawalla and Neeraj Sood
-
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
By Tomas Philipson and Anupam B. Jena